A recent study reveals that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop traditional diet and exercise programs.
Research printed in a leading medical journal demonstrates that while overweight individuals often shed about a fifth of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing these drugs should be informed of the danger of fast rebound weight gain when the medication concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery means a reversion to starting weight in about one and a half years.
Comparing Therapies
The study, which reviewed dozens of trials involving thousands of patients, compared the outcomes of these new drugs with conventional dieting.
Scientists note that individuals who lose weight through dieting usually experience a less rapid weight regain—approximately 100 grams monthly—once they finish.
Understanding the Quick Regain
Nutrition scientists believe the mechanism of the jabs explains the amplified rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the system to produce less of its own natural hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means appetite is no longer kept in check, making excessive eating a significant risk."
An Ongoing Condition?
Health authorities suggest the injections for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals contend that, given the likelihood of relapse, the therapy is often life-long.
This opinion is echoed by pharmaceutical companies, who note that the findings "highlight the chronic nature of obesity," similar to managing conditions like diabetes.
Patient Experiences
Individuals who have stopped the jabs describe a sudden return of cravings.
"I experienced a switch activating and you become starving," described a patient.
The struggle is exacerbated if individuals have not developed sustainable dietary or behavioural changes during therapy.
Widespread Interest
Survey data show that a significant number of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone solution and lasting health benefits likely depends on integrated lifestyle management.
